Lyra Therapeutics, Inc. LYRA
0.19 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
0.35 +0.16 +84.47%
After hours · Nov 4, 4:00 PM ET
0.3623 Day range 0.52
0.0004 52-week range 5.65
- YTD
- -93.83%
- 1 year
- -96.70%
Financial health
Altman Z-Score
-19.16 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -0.2×
FY 2018 5y median -65.1× FY 2025
P/S 120×
FY 2018 5y median 3483× FY 2025
P/B -4.5×
FY 2018 5y median 58.8× FY 2025
P/FCF -1.7×
FY 2018 5y median -96.9× FY 2025
EV/EBITDA -2.1×
FY 2018 5y median -65.4× FY 2025
EV/Sales 156×
FY 2018 5y median 3462× FY 2025
FCF Yield -60.6%
FY 2018 5y median -1.0% FY 2025
Profitability
Gross Margin 100.0%
FY 2018 5y median 100.0% FY 2025
Operating Margin -7794.5%
FY 2018 5y median -6280.8% FY 2025
Net Margin -7266.1%
FY 2018 5y median -6090.9% FY 2025
ROE 269.8%
FY 2018 5y median -70.1% FY 2025
ROIC -98.8%
FY 2018 5y median -98.8% FY 2025
ROA -80.1%
FY 2018 5y median -79.3% FY 2025
Growth (YoY)
Revenue -74.1%
FY 2018 FY 2025
Operating Income 67.8%
FY 2018 FY 2025
EPS (diluted) -1202.1%
FY 2018 FY 2025
Free Cash Flow 60.0%
FY 2018 FY 2025
Financial Health
Current Ratio 1.7×
FY 2018 5y median 3.4× FY 2025
Quick Ratio 1.7×
FY 2018 5y median 3.4× FY 2025
Debt / Equity -2.8×
FY 2018 5y median 0.1× FY 2025
Net Debt / EBITDA -0.5×
FY 2018 5y median 0.1× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
